EXOSENS: directors' dealings · France · AMF

About EXOSENS

EXOSENS is a French high-tech industrial group focused on mission-critical electro-optical technologies. The company designs, manufactures and sells advanced solutions for amplification, detection and imaging, serving demanding environments where reliability, sensitivity and rugged performance are essential. Its product portfolio includes image intensifier tubes for night vision, traveling wave tubes, advanced cameras, neutron and gamma detectors, and instrument detectors. The company is particularly exposed to defense and surveillance applications, while also addressing industrial control, life sciences and nuclear-related markets. The group’s roots go back to 1937, when it began operating as a Philips subsidiary under the name Hyperelec in Brive-la-Gaillarde, France. It left the Philips group in 1998, later became part of the Photonis heritage in 2005, and adopted the EXOSENS name in September 2023. EXOSENS was listed on Euronext Paris, Compartment A, on 7 June 2024. The IPO was used in part to reduce leverage and improve financial flexibility, supporting the group’s next phase of expansion. Growth has been supported by an active acquisition strategy. EXOSENS acquired Xenics in 2022, followed by ProxiVision, Telops and El-Mul in 2023. In 2024, it added Centronic and LR Tech, and in 2025 completed the acquisitions of Noxant, NVLS and Phasics. These transactions broadened the group’s technological base, strengthened its photonics platform and added capabilities such as high-performance cooled infrared cameras, defense optics and complementary sensing technologies. Today, EXOSENS operates with a meaningful international footprint. The group states it has production and R&D activities across 12 sites in Europe and North America and more than 1,800 employees. Management highlights more than 85 years of expertise in electro-optics and a recognized position as an innovator in highly specialized niche markets. Defense & Surveillance accounted for 75% of 2025 revenue, underscoring the strategic importance of this segment and the structural demand linked to night vision and digital imaging. Financially, EXOSENS delivered a strong 2025 performance, exceeding guidance with revenue up 22.1% to €468.2 million, adjusted EBITDA of €151.6 million and free cash flow of €57.3 million. This combination of growth, margin expansion and cash generation reflects a business model centered on innovation, disciplined industrial execution and exposure to defense-driven demand. As a listed French specialist, EXOSENS stands out as a focused photonics and defense technology platform with long operating history and significant upside potential from capacity expansion and M&A integration.